Department of Medicine Solna, Karolinska Institutet and Department of Cardiology Karolinska University Hospital, Stockholm, Sweden; Inserm U1116, Nancy, France; Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France.
Paris-Descartes University, AP-HP, Diagnosis and Therapeutic Center, Hôtel Dieu, Paris, France.
EBioMedicine. 2024 May;103:105107. doi: 10.1016/j.ebiom.2024.105107. Epub 2024 Apr 17.
The cardio-ankle vascular index (CAVI) measure of arterial stiffness is associated with prevalent cardiovascular risk factors, while its predictive value for cardiovascular events remains to be established. The aim was to determine associations of CAVI with cardiovascular morbimortality (primary outcome) and all-cause mortality (secondary outcome), and to establish the determinants of CAVI progression.
TRIPLE-A-Stiffness, an international multicentre prospective longitudinal study, enrolled >2000 subjects ≥40 years old at 32 centres from 18 European countries. Of these, 1250 subjects (55% women) were followed for a median of 3.82 (2.81-4.69) years.
Unadjusted cumulative incidence rates of outcomes according to CAVI stratification were higher in highest stratum (CAVI > 9). Cox regression with adjustment for age, sex, and cardiovascular risk factors revealed that CAVI was associated with increased cardiovascular morbimortality (HR 1.25 per 1 increase; 95% confidence interval, CI: 1.03-1.51) and all-cause mortality (HR 1.37 per 1 increase; 95% CI: 1.10-1.70) risk in subjects ≥60 years. In ROC analyses, CAVI optimal threshold was 9.25 (c-index 0.598; 0.542-0.654) and 8.30 (c-index 0.565; 0.512-0.618) in subjects ≥ or <60 years, respectively, to predict increased CV morbimortality. Finally, age, mean arterial blood pressure, anti-diabetic and lipid-lowering treatment were independent predictors of yearly CAVI progression adjusted for baseline CAVI.
The present study identified additional value for CAVI to predict outcomes after adjustment for CV risk factors, in particular for subjects ≥60 years. CAVI progression may represent a modifiable risk factor by treatments.
International Society of Vascular Health (ISVH) and Fukuda Denshi, Japan.
动脉僵硬度的心血管踝臂指数 (CAVI) 测量与普遍存在的心血管危险因素相关,但其对心血管事件的预测价值仍有待确定。目的是确定 CAVI 与心血管发病率和死亡率(主要结果)和全因死亡率(次要结果)的相关性,并确定 CAVI 进展的决定因素。
TRIPLE-A-Stiffness 是一项国际多中心前瞻性纵向研究,在 18 个欧洲国家的 32 个中心招募了 >2000 名年龄≥40 岁的受试者。其中,1250 名受试者(55%为女性)随访中位数为 3.82(2.81-4.69)年。
根据 CAVI 分层的未调整累积发病率,最高分层(CAVI > 9)更高。经年龄、性别和心血管危险因素调整的 Cox 回归显示,CAVI 与心血管发病率和死亡率增加相关(每增加 1 个单位,风险比 1.25;95%置信区间,CI:1.03-1.51)和全因死亡率(每增加 1 个单位,风险比 1.37;95%CI:1.10-1.70)在≥60 岁的受试者中。在 ROC 分析中,CAVI 的最佳阈值为 9.25(c 指数 0.598;0.542-0.654)和 8.30(c 指数 0.565;0.512-0.618),分别用于预测≥60 岁或<60 岁的受试者中 CV 发病率和死亡率增加。最后,年龄、平均动脉压、抗糖尿病和降脂治疗是在调整基线 CAVI 后预测每年 CAVI 进展的独立预测因素。
本研究发现,在调整心血管危险因素后,CAVI 对预测结果具有额外的价值,特别是对于≥60 岁的患者。CAVI 进展可能是一种可通过治疗改变的危险因素。
国际血管健康学会(ISVH)和日本福岛电子。